Alyeska Investment Group
ATXS

Alyeska Investment Group’s Astria Therapeutics ATXS Stock Holding History

Alyeska Investment Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,770
Closed -$160K – 466
2023
Q4 		$160K Buy
+20,770
New +$115K ﹤0.01% 483
2021
Q2 		– Sell
-187,437
Closed -$3.25M – 722
2021
Q1 		$3.25M Buy
187,437
+179,104
+2,149% +$3.24M 0.04% 394
2020
Q4 		$107K Hold
8,333
– – ﹤0.01% 494
2020
Q3 		$310K Sell
8,333
-179,167
-96% -$7.1M ﹤0.01% 435
2020
Q2 		$7.23M Hold
187,500
– – 0.11% 226
2020
Q1 		$4.67M Hold
187,500
– – 0.09% 196
2019
Q4 		$6.65M Hold
187,500
– – 0.09% 202
2019
Q3 		$6.08M Hold
187,500
– – 0.09% 206
2019
Q2 		$9.08M Hold
187,500
– – 0.12% 179
2019
Q1 		$8.91M Buy
187,500
+20,833
+12% +$706K 0.12% 186
2018
Q4 		$4.37M Buy
166,667
+150,000
+900% +$5.68M 0.06% 237
2018
Q3 		$800K Hold
16,667
– – 0.01% 361
2018
Q2 		$959K Buy
+16,667
New +$1.54M 0.01% 402

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alyeska Investment Group's ATXS Position: Q4 2022 in Review

Alyeska Investment Group sold out of Astria Therapeutics (ATXS) in Q4 2022, closing a stake of 274,719 shares — an estimated $2.48M sold.

Alyeska Investment Group first reported a position in ATXS in Q2 2015 and held it in 19 quarters. The position peaked at $2.63M in Q2 2021. 61 funds tracked by Wall St. Rank hold ATXS as of Q4 2022.

  • Alyeska Investment Group reported no remaining Astria Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 274,719 Astria Therapeutics shares in Q4 2022, an estimated $2.48M.
  • Alyeska Investment Group first reported a position in Astria Therapeutics in Q2 2015 and held it in 19 quarters.
  • Alyeska Investment Group's Astria Therapeutics position peaked at $2.63M in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2022.

Based on Alyeska Investment Group's 13F filing for Q4 2022, filed 14 Feb 2023.